Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) mid-day: Editas Medicine (EDIT) CEO Resigns — collapsing gene editing peer group

January 22, 2019

EDIT (-$4.48 or -17.13%), Intellia Therapeutics (NTLA -$1.05 or -6.88%) and CRISPR Therapeutics (CRSP -$4.07 or -10.96%) equities plunged    EDIT volume is HIGH with 3.7 M shares traded <3 month average = 792.8 K shares, CRSP volume is also HIGH with 1.79 M shares traded <3 month average = 834.7 K shares> and NTLA volume is as LOWER with 577.05 K shares traded <3 month average = 694.3 K shares>

RegMed Investors’ (RMi): worried about 2019, investors better be!

January 21, 2019

   RMi is the source investors and traders need – it’s more than opinion; the facts and truth need to be recognized! I post about “indication intelligence” devoting my time to collection and analysis of information for insight into sector vulnerabilities and strengths.   My writing is “that warning analysis is NOT a commodity. However, there are times, when the likelihood of conclusions are inescapable!        

Stemline Therapeutics (STML) priced an 8.88 M share offering at $9.00 per share

January 16, 2019

STML closed up at $0.86 (+9.47%) to $9.94 Expected gross proceeds to Stemline are $80 million. Due to demand, this offering was upsized from the previously announced 6,600,000 shares. STML has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. BUY

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.